MARLBOROUGH, Mass., Sept. 17, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Silk Road Medical, Inc. (Nasdaq: SILK), a medical device company that pioneered a new approach for stroke prevention and the treatment of carotid artery disease through a minimally invasive procedure called transcarotid artery revascularization (TCAR). "Completing this acquisition enables Boston Scientific to strengthen our vascular technology solutions by bringing the ...

NEW YORK, Aug. 20, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Silk Road Medical, Inc. (Nasdaq: SILK), relating to its proposed merger with Boston Scientific Corporation and Seminole Merger Sub. Under the terms of the agreement, Silk Road stockholders wi ...

MONSEY, N.Y., Aug. 19, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP has renewed its investigation into the fairness of the proposed sale of Silk Road Medical, Inc. (Nasdaq: SILK) ("SILK") to Boston Scientific Corporation for $27.50 per share in cash. On July 29, 2024, SILK filed a definitive proxy concerning the proposed sale with the SEC. Based on our review of the proxy, we have renewed our investigation into whether there are any undisclosed potential conflicts of interest. If you remain ...

Silk Road Medical (SILK) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.35 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -10.53%. A quarter ago, it was expected that this medical device maker would post a loss of $0.40 per share when it actually produced a loss of $0.36, delivering a surprise of 10%. Over the last four quarters, the compa ...

Financial Performance - Revenue for Q2 2024 was $51.2 million, an increase of $5.9 million or 13% compared to Q2 2023[1] - Gross profit for Q2 2024 was $38.5 million, with a gross margin of 75%, up from 71% in Q2 2023[2] - Operating expenses increased by 20% to $55.7 million in Q2 2024, compared to $46.6 million in the same period last year[2] - Net loss for Q2 2024 was $16.6 million, or $0.42 per share, compared to a loss of $13.5 million, or $0.35 per share, in Q2 2023[2] - Adjusted EBITDA loss improved to $1.1 million in Q2 2024 from a loss of $3.4 million in Q2 2023[2] Cash and Assets - Cash, cash equivalents, and investments totaled $186.2 million as of June 30, 2024[2] - Total assets as of June 30, 2024, were $269.8 million, up from $265.3 million at the end of 2023[9] - The accumulated deficit increased to $430.2 million as of June 30, 2024, from $399.5 million at the end of 2023[9] Research and Development - Research and development expenses for Q2 2024 were $11.9 million, compared to $10.8 million in Q2 2023[8] Guidance and Acquisitions - The company has withdrawn its full year 2024 financial guidance due to the proposed acquisition by Boston Scientific[3]

Studied across thousands of patients and supported by hundreds of clinical publications, the TCAR pioneer has continually delivered positive outcomes through minimally invasive techniques SUNNYVALE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. ("Silk Road") (NASDAQ:SILK), a leading minimally invasive medical device company focused on reducing the risk and impact of stroke, today announced the milestone that more than 100,000 TCAR procedures have been performed to date. Since its incepti ...

NEW YORK, July 29, 2024 /PRNewswire/ -- 1. Do you file class actions and go to Court? 2. When was the last time you recovered money for shareholders? 3. What cases did you recover money in and how much? Contact: Juan Monteverde, Esq. MONTEVERDE & ASSOCIATES PC The Empire State Building 350 Fifth Ave. Suite 4740 New York, NY 10118 United States of America [email protected] Tel: (212) 971-1341 Click here for more information https://monteverdelaw.com/case/silk-road-medical-inc/. It is free and there is no cos ...

NEW YORK, July 19, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies. Kuehn Law is investigating whether the Boards of the below companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process: Silk Road Medical, Inc. has agreed to merge wi ...

Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court. Contact: Juan Monteverde, Esq. MONTEVERDE & ASSOCIATES PC The Empire State Building 350 Fifth Ave. Suite 4740 New York, NY 10118 United States of America jmonteverde@monteverdelaw.com Tel: (212) 971-1341 Attorney Advertising. (C) 2024 Monteverde & A ...

If you remain a SILK shareholder and question the fairness of the price, you may contact our firm at the following link to discuss your legal rights at no charge: "We are investigating whether the SILK Board of Directors acted in the best interests of SILK shareholders in approving the sale," explained Joshua Fruchter, a founding partner of Wohl & Fruchter. "This includes whether the price agreed upon is fair to SILK shareholders, as well as whether all material information regarding the transaction has bee ...